Retatrutide Produces Substantial Weight Loss and Improves Glycaemic Control in Obesity With Type 2 Diabetes: TRIUMPH-2 Study Written By Dr. Kamal Kant Kohli3 Oct 2026 9:00 AM ISTNew research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28-Oct 2) and...
USFDA Approves Eli Lilly's Mounjaro to Cut Heart Attack, Stroke Risk in High-Risk Type 2 Diabetes Patients Written By sheeba farhat29 Aug 2026 8:06 PM ISTBengaluru: Eli Lilly said on Friday the U.S. FDA has approved its diabetes drug Mounjaro to reduce the chances of heart attack or stroke in adults...
Eli Lilly Sues 6 Firms Over Alleged Black-Market Sale of Unapproved Obesity Drug Retatrutide Written By MD Bureau13 Aug 2026 11:15 AM ISTNew Delhi: Eli Lilly on Wednesday said it had filed six lawsuits against U.S. companies it accuses of illegally selling black-market versions of its...
Eli Lilly Allows Limited Early Access to Retatrutide Prior to USFDA Approval Written By sheeba farhat5 Aug 2026 9:11 PM ISTLos Angeles: Eli Lilly said on Monday it would allow a limited number of patients to have early access to its experimental obesity drug, retatrutide,...
Retatrutide Produces More Than 20% Weight Loss in Phase 3 Trials Written By Dr Kartikeya Kohli25 July 2026 12:45 PM ISTTopline results from two phase 3 trials showed that retatrutide produced substantial weight loss in adults with obesity, including those with type 2...
Retatrutide Shows Remarkable Weight Loss in Phase 3 TRIUMPH-1 Trial Written By Dr Kartikeya Kohli23 May 2026 8:45 AM ISTIn the phase 3 TRIUMPH-1 trial, 2339 adults with obesity or overweight and at least one weight-related comorbidity were randomized to receive...
Lilly's Retatrutide Shows Strong Sugar, Weight Loss Gains in Late-Stage Trial Written By sheeba farhat21 March 2026 10:30 AM ISTBengaluru: Eli Lilly's next-generation obesity drug showed a reduction in blood sugar levels during a late-stage trial, the drugmaker said on...
Retatrutide Shows Strong Glycemic Control and Weight Loss in Phase 3 Trial Written By Dr. Kamal Kant Kohli21 March 2026 8:45 AM ISTRetatrutide demonstrated promising results in its first late-stage trial for Type 2 Diabetes, reducing HbA1c levels by up to 2% and achieving an...
Eli Lilly Announces USD 3.5 Billion US Manufacturing Facility for Next-Gen Obesity Drugs Written By sheeba farhat31 Jan 2026 5:27 PM ISTNew Delhi: Eli Lilly announced on Friday that it will build a pharmaceutical manufacturing facility in Pennsylvania, its fourth new site in an effort...
Retatrutide effects greatest Weight Loss in TRIUMPH-4 trial, bests Tirzepatide Written By Medha Baranwal13 Dec 2025 11:15 AM ISTUSA: A first-in-class triple hormone receptor agonist, retatrutide, has demonstrated striking reductions in body weight along with meaningful...
CDSCO Panel Approves Eli Lilly's Protocol Amendment Proposal for Retatrutide study Written By Dr. Divya Colin19 Jan 2025 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol...
CDSCO Panel Approves Eli Lilly's Protocol Amendment Proposal for Antidiabetic Drug Retatrutide study Written By Dr. Divya Colin29 Dec 2024 6:15 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Eli...
